AB0874 Outcomes of Fluoroscopic Sacroiliac Joint Injections (Patients Views). (10th June 2014)

• Record Type: Journal Article
• Authors: Al-Rubae, R.; Chattopadhyay, C.
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 1090
• Page End: 1091
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.1243
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The sacroiliac joint has been shown to be a source of pain in 10% to 27% of suspected cases with chronic low back pain utilizing controlled comparative local anesthetic blocks. Sacroiliac joint steroid injection is a well-known treatment option, yet it is not that widely used. We are trying to show its benefits from patients' perspective and emphasize its importance as a treatment option. Methods: We audited one hundred patients who had Sacroiliac joint injections under X-RAY guidance between 2007 and 2012 in Wrightington hospital by sending patient questionnaire with reply envelope. We have received thirty-nine replies. Results: Results showed that 26 out of 39 patients (66.6%) found the injection very useful. Among those 26 patients (12.8%) reported that the pain completely resolved while (46.1%) reported more than 50% of pain improvement post injection, (10.2%) reported 25% of improvement while (15.3%) reported no improvement and 6 patients didn't comment. Among the 39 patients audited 32.5% reported pain improvement lasted for more than 6 months and 41% experienced pain improvement between 1-3 months, only one patient reported no improvement and the rest didn't comment. Finally 23 out of 39 patients (58.9%) reported reduction in long-term usage of painkillers after having the injection. Conclusions: The study shows encouraging results that the fluoroscopic sacroiliac injection should be considered more often and be available to a wider range of patients. It is hoped that this procedure will be considered as an adjunct management of back pain. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.1243